Scientists at the University of California, Riverside, have devised potent chemical agents 135H11 and 135H12 that can thwart cancer metastasis, bringing research closer to drug development.
A comparison of two of the most common combination therapies for locally advanced prostate cancer show the more aggressive option is linked with a higher rate of survival.
Representing a paradigm shift in thoracic surgery, the hybrid operating room combines three techniques into a single appointment eliminating multiple clinical visits for improved patient experience and outcomes.
Results of a new international survey of more than 2,500 responders from five countries show that women know more about men's health issues than men do, men have poor knowledge of key urological symptoms and don't take early signs of potentially life-threatening urological conditions seriously. The low level of awareness indicated by the survey is of particular concern as urological conditions are on a rise due to the ageing European population.
Genomic screening of more than 50,000 people shows that more than 80 percent of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. Researchers found evidence that mutations in the tumor suppressor gene SPOP contribute to cancer by disrupting a process called liquid-liquid phase separation. Liquid-liquid phase separation is seen often in nature and is the reason why oil and vinegar separate in salad dressing.
Leveraging advances in mRNA and nanotechnology, investigators demonstrate that tumor suppressor PTEN can be restored in preclinical models of prostate cancer.
Researchers examined the costs associated with screening for prostate cancer, including treatment, for three years after diagnosis. They estimated that for men diagnosed in each of 2004, 2005, 2006, and 2007, the total cost for treating and screening for each group would be $1.2 billion for three years after diagnosis.
The American Association for Cancer Research (AACR) releases its annual Cancer Progress Report highlighting how federally funded research discoveries are fueling the development of new and even more effective ways to prevent, detect, diagnose, and treat cancer.
A research team at the University of Turku in Finland discovered a link between the interplay of certain simultaneously occurring genetic changes in the HOXB13 and CIP2A genes, aggressiveness of prostate cancer, high risk of developing the disease, and poorer survival rates of patients. Prostate cancer is a major challenge in health care with over one million new cases and 300,000 deaths from it each year worldwide.